Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Sjogren's Syndrome, Keratoconjunctivitis Sicca
Interventions
Levocarnitine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogren's Syndrome
Interventions
HZN-1116, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Mesa, Arizona • Phoenix, Arizona • Napa, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogren's Syndrome, Salivary Gland
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
12 Years and older
Enrollment
1,740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Primary Sjögren's Syndrome
Interventions
S95011 concentrate for solution for infusion, Placebo concentrate for solution for infusion
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Lakewood, Colorado • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced May 21, 2026, 6:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
Conditions
Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Primary Sjögren Syndrome, Dry Eye
Interventions
0.005% Lacripep, 0.01% Lacripep, Placebo
Drug
Lead sponsor
TearSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Azusa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced May 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced May 21, 2026, 6:55 PM EDT
Not yet recruiting No phase listed Observational
Conditions
Dry Eye, Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogrens Syndrome
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
43
States / cities
Chula Vista, California • Fullerton, California • La Palma, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Healthy Volunteers, Sjögren's Syndrome
Interventions
ASP5502, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Dry Eye, Dry Eye Syndromes, Sjogren's Syndrome
Interventions
Cyclosporine 0.09% Ophthalmic Solution
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Primary Sjogren's Syndrome
Interventions
tibulizumab (LY3090106)
Drug
Lead sponsor
Matthew C. Baker
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis
Interventions
Eye Exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjögren's Syndrome
Interventions
VIB4920, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Fullerton, California • Upland, California • Lawrenceville, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogren's Syndrome, Salivary Gland, Pathogenesis
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
16 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogren's Syndrome, Dysautonomia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced May 21, 2026, 6:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogren's Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Interventions
SAR441344, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced May 21, 2026, 6:55 PM EDT
Conditions
Sjogren's Syndrome, Neonatal Systemic Lupus Erythematosus, Fetal Heart Block Complete
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced May 21, 2026, 6:55 PM EDT